LDS/Medical Tests/Cyclobenzaprine, Urine

Cyclobenzaprine, Urine

Cyclobenzaprine is a tricyclic compound. Cyclobenzaprine differs from the tricyclic antidepressant amitriptyline by only a double bond in the cycloheptane ring. However, despite the structural similarities, cyclobenzaprine does not possess the antidepressant effects.

The typical route of administration is oral. Cyclobenzaprine is metabolized extensively. Metabolites that may appear in the urine include norcyclobenzaprine, 3-hydroxycyclobenzaprine, cyclobenzaprine-N-oxide, and glucuronide conjugates. The half-life of cyclobenzaprine is 1-3 days.

Approximately 50% of an oral dose appears in the urine over the subsequent 5 days. Elimination depends on factors such as drug formulation dose, dose frequency, clinical status and pharmacokinetics of the individual patient.

Common side effects: drowsiness, dizziness, dry mouth, headache, blurred vision, tachycardia, and confusion. Overdose effects include agitation, psychosis, hallucinations, fever, seizures, cardiac arrhythmias, confusion, coma, and possible death.

Cyclobenzaprine can be detected in urine by a variety of analytical methods (see below); both qualitative and quantitative tests are available.

  • Adherence monitoring
  • Drug abuse evaluation
  • Toxicity/Overdose assessment
A qualitative positive result indicates only the presence of cyclobenzaprine and does not necessarily correlate with the extent of physiological and psychological effects, nor does it predict the dose that was taken or administered. Any result that is inconsistent with clinical expectations should be confirmed or quantitated by a second method.

Therapeutic levels: 0.01-0.03 mg/L

Toxic levels: Data not available

Note: therapeutic ranges and toxic thresholds are best evaluated from blood samples. Quantitative results obtained with blood samples collected at specific times after drug administration are preferred for pharmacokinetic analyses.

   

Cut-Off Ranges

Cut-off values are used to determine the positivity of the urine specimen being analyzed. Cut-off values can vary based on the particular method of analysis that is used for detection, the laboratory, or whether the test is a qualitative or quantitative method. Detection will be improved with low cutoff concentrations. The testing laboratory cut-off range is listed on the patient report.

Many, including Liquid Chromatography/Mass Spectroscopy (LC/MS, LC-MS/MS), Gas Chromatography/Mass Spectroscopy (GC/MS), or Thin Layer Chromatography (TLC). Immunoassays (IA) specific for cyclobenzaprine are not available. However, cyclobenzaprine is detected by many immunoassays designed to detect tricyclic antidepressants. This drug is a common reason for “false positive” results in tricyclic antidepressant tests. Laboratories may include a pre-analytical hydrolysis reaction to liberate the glucuronide conjugates, which may improve detection.

Fresh urine specimen (random) collected in either a clean glass or plastic container. An acceptable urine specimen submitted for testing should be in the pH range of 3-11. Creatinine or specific gravity results will identify dilute specimens. Adulteration of the urine specimen can result in erroneous results.

Stability

  • Ambient: 5 days
  • Refrigeration: 7 days
  • Frozen: 30 days
Pharmacogenetic testing such as genotyping for *CYP3A4, CYP3A5, CYP2D6, CYP2C9,* and *CYP2C19* variants could guide drug and dose selection. Supportive testing such as a liver profile, kidney profile, comprehensive metabolic panel, CBC, and testing for concomitant drugs may be appropriate.
1-3 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
  • Baselt RC (ed). Disposition of toxic drugs and chemicals in man, 9th ed. Seal Beach, CA: Biomedical Publications; 2011.
  • Brunton LL, Chabner B, Knollman B (eds). Goodman and Gilmans’ the pharmacological basis of therapeutics, 12th ed. New York: McGraw-Hill; 2010.